| Schedule of basic and diluted net loss per share |
| Schedule of basic and diluted net loss per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Three Months Ended
September 30,
|
|
|
Nine Months Ended
September 30,
|
|
| |
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
|
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net income (loss) |
|
$ |
9,888 |
|
|
$ |
(23,314 |
) |
|
$ |
(44,608 |
) |
|
$ |
(74,069 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator - basic: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Weighted average common shares outstanding |
|
|
74,605,474 |
|
|
|
72,572,138 |
|
|
|
74,554,552 |
|
|
|
72,415,546 |
|
| Denominator – diluted: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Weighted average common shares outstanding |
|
|
80,141,678 |
|
|
|
72,572,138 |
|
|
|
74,554,552 |
|
|
|
72,415,546 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net income (loss) per share - basic |
|
$ |
0.13 |
|
|
$ |
(0.32 |
) |
|
$ |
(0.60 |
) |
|
$ |
(1.02 |
) |
| Net income (loss) per share - diluted |
|
$ |
0.12 |
|
|
$ |
(0.32 |
) |
|
$ |
(0.60 |
) |
|
$ |
(1.02 |
) |
|
| Schedule of anti-dilutive net loss per share |
| Schedule of anti-dilutive net loss per share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Three Months Ended
September 30,
|
|
|
Nine Months Ended
September 30,
|
|
| |
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
| Stock options outstanding |
|
|
7,335,035 |
|
|
|
7,931,652 |
|
|
|
7,335,035 |
|
|
|
7,931,652 |
|
| Non-vested shares of restricted stock |
|
|
4,059,869 |
|
|
|
6,360 |
|
|
|
4,059,869 |
|
|
|
6,360 |
|
| Warrants(a)
|
|
|
12,045,000 |
|
|
|
21,045,775 |
|
|
|
17,855,467 |
|
|
|
21,045,775 |
|
| Convertible notes(a)
|
|
|
9,729,163 |
|
|
|
9,729,163 |
|
|
|
9,729,163 |
|
|
|
9,729,163 |
|
|
(a) |
The public and private warrants and Convertible Notes referred to in Notes 11 and 14 were excluded on an as converted basis because their
effect would have been anti-dilutive for the three and nine months ended September 30, 2023. The Fortress warrants referred to in Notes 11 and 14 were also excluded on an as converted basis
because their effect would have been anti-dilutive for the nine months ended September 30, 2023. |
|